Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

General Inclusion Criteria: 1. Age ≥ 18 years 2. Patient has been informed of the nature of the study and agrees to its provisions, has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site 3. Ischemic heart disease with an indication for a PCI with, if available and per hospital guidelines, Heart Team consensus for a PCI procedure 4. Intention to treat all lesions requiring a PCI with the Ultimaster Nagomi stent Complex Procedure Inclusion Criteria Subject meets ≥ 1 of the complex procedure criteria: 1. Multivessel PCI defined as ≥ 2 native coronary arteries and/or venous or arterial bypass grafts treated with a stent 2. ≥ 3 stents implanted 3. ≥ 3 lesions treated 4. Complex bifurcation lesion defined as true bifurcation lesion (Medina 1.1.1, 1.0.1 or 0.1.1) with a side branch diameter ≥ 2.5 mm plus one of the following: i) side branch disease \> 10 mm ii) calcified lesion iii) thrombotic lesion e) Bifurcation lesion implanted with two stents f) Total stent length implanted \> 60 mm g) Chronic total occlusion defined as a 100% occlusion with antegrade TIMI 0 flow with at least a 3-month duration h) Left main stenting (main stem and/or bifurcation) i) In-stent restenosis j) Severe calcified lesion with use of atherectomy, lithotripsy or cutting balloon Exclusion Criteria: 1. Any surgery requiring general anaesthesia, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines 2. Hypersensitivity or contraindication to aspirin, heparin, L605 cobalt-chromium alloy, sirolimus or its structurally related compounds, lactide polymers or caprolactone polymers that cannot be pre-medicated 3. Known contrast sensitivity that cannot be premedicated 4. Pregnant and breastfeeding women 5. Life expectancy \< 1 year for any cardiac or non-cardiac cause 6. Participation in another clinical study that has not yet completed its primary endpoint 7. Earlier enrolment in the Nagomi Complex study 8. Unlikely to be available for follow-up during the duration of the study (2 years)